



CHRONIC COMPLICATIONS IN DIABETES MELLITUS

CPT Thomas Oliver, M.D.
Endocrinology, Diabetes and
Metabolism Service
Walter Reed Army Medical
Center



DM COMPLICATIONS - EPIDEMIOLOGY

◆ MAJOR DETERMINING

FACTORS

- ❖ Duration**
- ❖ Glycemic Control**
- ❖ Type 1 vs. Type 2**



DM COMPLICATIONS - GLYCEMIC CONTROL IN TYPE 1

- ♦ **DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT)**
 - ❖ 1441 pts. with type 1 DM
 - ❖ 726 within 5 years of onset = 0 comp's
 - ❖ Comparison of intensive therapy vs.... conventional therapy
 - ❖ Mean follow-up 6.5 years (4-9) with 98% data collection



DM COMPLICATIONS

- GLYCEMIC CONTROL IN TYPE 1

- ◆ **DIABETES CONTROL AND COMPLICATIONS TRIAL (DCCT)**
- ◆ **INTENSIVE THERAPY MEANS**
 - ❖ **Subcutaneous Continuous Insulin Injection (pump) OR**
 - ❖ **Multiple daily injections AND**
 - ❖ **Monthly clinic visits**



DM COMPLICATIONS - GLYCEMIC CONTROL IN TYPE 1

- ◆ **DCCT RESULTS:**
- ◆ **INTENSIVE GROUP:**
 - ❖ HgA1c avg..... 7.2%
 - ❖ FS avg..... 155 mg/dl
- ◆ **CONVENTIONAL GROUP:**
 - ❖ HgA1c avg..... 9.1%
 - ❖ FS avg..... 231 mg/dl



DM COMPLICATIONS

- GLYCEMIC CONTROL IN TYPE 1

- ♦ **DCCT RESULTS:**
- ❖ **In Intensive Group:**
- ❖ **Retinopathy progressed by 3 steps in 70.3% fewer patients.**
- ❖ **Initial appearance of retinopathy was reduced by 27%.**
- ❖ **Need for laser photocoagulation reduced by 56%.**



DM COMPLICATIONS

- GLYCEMIC CONTROL IN TYPE 1

♦ DCCT RESULTS:

❖ In Intensive Group:

- ❖ Nephropathy (albuminuria > 300 mg/d) reduced by 54%.
- ❖ Neuropathy (Nerve conduction abnormalities + clinical sx.) reduced by 64%.



DM COMPLICATIONS

- GLYCEMIC CONTROL IN TYPE 1

- ♦ **DCCT RESULTS:**
- ❖ In Intensive Group:
- ❖ Macrovascular events (cardiac & peripheral) reduced; though not to statistically significant level.
- ❖ Significant LDL elevation (>160 mg/dl) reduced by 35%.



DM COMPLICATIONS

- GLYCEMIC CONTROL IN TYPE 2

- ◆ DCCT looked at Type 1 only!
- ◆ Can we apply findings to type 2?
- ◆ Studies:
 - ❖ Small Japanese study with 110 patients shows results similar to DCCT.
 - ❖ UKPDS



- Microvascular Disease
 - Delayed retinopathy
 - ▢ Delayed nephropathy
- ▢ Macrovascular Disease
 - ▢ No effect on:
 - Cardiovascular disease
 - ▢ Diabetes-related deaths
 - ▢ All-cause mortality
 - ▢ Difference in HGB-A1C(0.9%)



UKPDS

- Macrovascular Disease
 - Metformin + Sulfonylurea detrimental
- ▢ Metformin monotherapy showed significant benefit on:
 - ▢ Cardiovascular disease
 - ▢ Diabetes-related death
 - ▢ All cause mortality



DM COMPLICATIONS - MECHANISMS

- ♦ **Many different tissues involved - nerves, skin, retina, kidney, heart, brain.**
- ♦ **Common to all of these are:**

BLOOD VESSELS



DM COMPLICATIONS - MECHANISMS

- ◆ **Microvascular Damage Affects:**
 - ❖ **Retinas**
 - ❖ **Glomeruli**
 - ❖ **Nerves**



DM COMPLICATIONS - MECHANISMS

- ♦ **Microvascular Damage Causes:**
 - ❖ **Blindness**
 - ❖ **End-Stage Renal Disease**
 - ❖ **Neuropathy >>> Amputations**



DM COMPLICATIONS - MECHANISMS

- ◆ **Macrovascular Damage Affects**

Large (Named) Arteries:

- ◆ **Coronary Arteries**

- ◆ **Carotid/Cerebral Arteries**

- ◆ **Lower Extremity Arteries**



DM COMPLICATIONS - MECHANISMS

- ♦ **Macrovascular Damage Causes:**
 - ❖ **Angina, Myocardial Infarction, Sudden Death**
 - ❖ **Strokes**
 - ❖ **Poor Healing from Wounds or Infections >>> Amputations**



DM COMPLICATIONS - MECHANISMS

- ♦ So HOW does diabetes damage blood vessels?
- ♦ Best understood mechanism is by non-enzymatic glucosylation (glycation) of proteins and other macromolecules.
- ♦ Other mechanisms postulated include changes in NADP⁺ and NADH levels associated with alternative glucose metabolic fates when usual pathways are saturated.



DM COMPLICATIONS - MECHANISMS

- ♦ **Chronic hyperglycemia causes increased glycation of proteins, resulting in Advanced Glycation Endproducts (AGEs)**
- ♦ **These can cause damage through loss of function, turning on/off signal pathways within cells, or alteration in gene expression.**



DM COMPLICATIONS - MECHANISMS

- ♦ **One of the proteins which is glycated is Hemoglobin. Because it is found in the blood, it is convenient to measure as HgA1c.**
- ♦ **Because RBCs (and thus Hg) survive in the blood for 90-120 days, the HgA1c provides a means to assess glycemic control over this period.**



DM COMPLICATIONS - MECHANISMS

- ♦ **The Role of Insulin**

- ❖ **High insulin levels as seen in insulin resistance MAY be contributory to the development of:**

- ♦ **Hypertension**

- ♦ **Atherosclerosis**



DM COMPLICATIONS - MECHANISMS

- ♦ **The Role of Insulin**
 - ❖ Hyperglycemia causes complications
 - ❖ Insulin causes complications
- ♦ **Type 1**
 - ❖ Usually not hyperinsulinemic; therefore concentrate on controlling hyperglycemia.
- ♦ **Type 2 (Actively under investigation)**
 - ❖ Unclear whether increasing insulin to achieve normal sugars overall benefit!!!



DM COMPLICATIONS - EYE DISEASE

- ♦ **8,000 new cases of blindness due to DM per year in the US.**
- ♦ **12% Cases of new blindness due to DM.**
- ♦ **Leading Cause of new Blindness in working-aged Americans.**



DM COMPLICATIONS - EYE DISEASE

- ♦ **Early Changes (normal exam)**
 - ❖ **Loss of Autoregulation of blood flow.**
 - ❖ **Decreased blood flow.**
 - ❖ **Loss of pericytes (supporting cells).**



DM COMPLICATIONS - EYE DISEASE

- ◆ **Nonproliferative Changes:**
 - ❖ **Dot & blot hemorrhages**
 - ❖ **Cotton-wool spots**
 - ❖ **Venous Loops**
 - ❖ **Venous Tortuosity**
- ◆ **100% incidence at 15 years**
 - ❖ **Increased retinal blood flow.**
 - ❖ **Capillary Dropout**



DM COMPLICATIONS - EYE DISEASE

♦ Proliferative Changes

- ❖ Neovascularization - most prominent at border between perfused and nonperfused retina.**
- ❖ Vitreous hemorrhage due to fragility of new vessels.**
- ❖ Contraction of co-existing glial tissue may lead to retinal detachment.**



DM COMPLICATIONS - EYE DISEASE

♦ Quiescent Stage

- ❖ End of Proliferative changes; vision usually stable at whatever level of loss was sustained during proliferative phase.
- ❖ **Laser photocoagulation** seems to accelerate transition from proliferative phase to quiescent phase. Intent is to arrive at quiescent phase with minimal loss of vision.



DM COMPLICATIONS - EYE DISEASE

♦ Macular Edema

- ❖ In DM, retinal vessels are more permeable.
- ❖ Fluid leakage from vessels to retina can cause localized edema.
- ❖ If present in the macula, can cause reduction in VA (20/20 > 20/50).
- ❖ Affects 300,000 pts/year.
- ❖ Risk can be decreased with laser rx.



DM COMPLICATIONS - EYE DISEASE

- ♦ **PREVENTION STRATEGIES:**
 - ❖ **Glycemic Control**
 - ❖ **Regular Eye Exams**
 - ❖ **Photocoagulation for Macular Edema or Neovascularization**



DM COMPLICATIONS - KIDNEY DISEASE

- ♦ **Leading Cause of End Stage Renal Disease (ESRD) in developed nations.**
- ♦ **27.2% Dialysis Patients have DM.**
- ♦ **36.4% NEW ESRD cases are related to DM.**
- ♦ **Familial clustering occurs.**



DM COMPLICATIONS - KIDNEY DISEASE

- ♦ **Type 1 vs. Type 2**
 - ❖ Previous studies suggested higher rate of ESRD in Type 1 pts.
 - ❖ More recent studies suggest ESRD rate in Type 2 pts. approaching that in Type 1 pts.



DM COMPLICATIONS - KIDNEY DISEASE

- ♦ **To B (for biopsy) or not to B**
- ♦ **Not needed in typical cases (~ 80%)**
 - ❖ **DM > 10 years**
 - ❖ **Other “opathies” present**
 - ❖ **Gradual progression**
- ♦ **Helpful in atypical cases**
 - ❖ **Within 10 yrs. onset of DM**
 - ❖ **Other indicators of inflammatory process**
 - ❖ **Rapid Progression**



DM COMPLICATIONS - KIDNEY DISEASE

- ♦ **Progression in Type 1 DM**
- ♦ **Glomerular Hyperfiltration**
 - ❖ **Renomegaly**
 - ❖ **GFR up to 140% of normal**
 - ❖ **Intermittent microalbuminuria
(with hyperglycemia)**



DM COMPLICATIONS - KIDNEY DISEASE

- ♦ **Progression in Type 1 DM**
- ♦ **Early Glomerular Lesions**
 - ❖ **Basement Membrane Thickening**
 - ❖ **Exercise-Induced Microalbuminuria**
 - ❖ **Begins ~ 18-24 months after onset DM**
 - ❖ **Lasts 4-15 years**



DM COMPLICATIONS - KIDNEY DISEASE

- ♦ **Progression in Type 1 DM**
- ♦ **Microalbuminuric Stage**
 - ❖ **30 - 300 mg Albumin/Day**
 - ❖ **GFR usually maintained**
 - ❖ **Associated with other organ damage**



DM COMPLICATIONS - KIDNEY DISEASE

- ◆ **Progression in Type 1 DM**
- ◆ **Clinical nephropathy**
 - ❖ **> 300-500 mg/day**
 - ❖ **Falling GFR (~1 ml/min/month)**
 - ❖ **Nephrotic Syndrome may occur**
 - * **>3500 mg/day**
 - * **Hypoalbuminemia**
 - * **Edema**
 - * **Hyperlipidemia**



DM COMPLICATIONS - KIDNEY DISEASE

- ♦ **Progression in Type 1 DM**
- ♦ **End Stage Renal Disease**
 - ❖ **Type 1 - 30-40% pts. after 20-30 years.**
 - ❖ **Onset within 2-3 years after nephrotic syndrome.**



DM COMPLICATIONS

- KIDNEY DISEASE

- ♦ **Progression in Type 2 DM**
- ♦ **Not as well-defined as for Type 1 due to unknown onset in many individuals.**
- ♦ **20-37% have microalbuminuria AT TIME OF DIAGNOSIS.**
- ♦ **Subgroups at higher risk include African-Americans, Hispanics, and Pima Indians.**



DM COMPLICATIONS - KIDNEY DISEASE

♦ Prevention Strategies:

- ❖ Normalize Blood Pressure
 - ❖ Goal 120-130/80-85
 - ❖ ACE inhibitors particularly beneficial
- ❖ Dietary Protein Restriction
 - ❖ 0.6-0.8 gm/kg/day in established macroalbuminuria or falling GFR
- ❖ Glycemic Control
- ❖ Regular Monitoring for Nephropathy
- ❖ Avoid Nephrotoxins (NSAIDs, some abx)



DM COMPLICATIONS - NEUROPATHIES

- ◆ **CNS Complications:**
- ◆ **Stroke**
 - ❖ **Increased Risk (independent of HTN, etc.)**
 - ❖ **Worsened neurologic injuries/deficits**
- ◆ **Diabetic Encephalopathy**
 - ❖ **Subtle cognitive defects**
 - ❖ **Possible increased risk from repeated episodes of severe hypoglycemia**
- ◆ **CNS infections - Mucormycosis**



DM COMPLICATIONS - NEUROPATHIES

- ◆ **Peripheral Neuropathies:**

- ◆ **Sensory Loss**

- ◆ **Pain Reception**

- ◆ **Pain, Paresthesias**

- ◆ **Loss of Sensation, Occult Injuries/Ulcers**

- ◆ **Position/Vibratory Sense**

- ◆ **Ataxia**

- ◆ **Increased Falls Risk**



DM COMPLICATIONS - NEUROPATHIES

♦ Peripheral Neuropathies:

❖ Motor Neurons

♦ Proximal Motor Neuropathy

- ❖ Pain/Anesthesia anterior thigh**
- ❖ Difficulty rising from squat/ climbing stairs**
- ❖ Knee Buckling**



DM COMPLICATIONS - NEUROPATHIES

- ♦ **Autonomic Neuropathies:**

- ♦ **Cardiovascular**

- ♦ **Postural Hypotension**
- ♦ **Resting Tachycardia**
- ♦ **Painless MI**

- ♦ **Respiratory**

- ♦ **Sleep Apnea**



DM COMPLICATIONS - NEUROPATHIES

♦ Autonomic Neuropathies:

❖ GastroIntestinal

- ♦ Esophageal Dysmotility**
- ♦ Gastroparesis**
- ♦ Pylorospasm**
- ♦ Intestinal - Diarrhea, Spasm**
- ♦ Gall Bladder Contractility**
- ♦ Anorectal Dysfunction - Incontinence**



DM COMPLICATIONS - NEUROPATHIES

- ♦ **Autonomic Neuropathies:**
 - ❖ **GenitoUrinary**
 - ♦ **Bladder Dysfunction**
 - ♦ **Male Impotence**
 - ♦ **Ejaculatory Disorders**
 - ♦ **Reduced Vaginal Lubrication,
Dyspareunia**



DM COMPLICATIONS - NEUROPATHIES

- ♦ **Prevention Strategies**
 - ❖ **Glycemic Control**
 - ❖ **Smoking Cessation**
 - ❖ **Regular Sensory Exams**
 - ❖ **Personal Protection**
 - ❖ **Consider Revascularization**
 - ❖ **Aggressive Treatment and Follow-Up of any Ulcers**



DM COMPLICATIONS - SUMMARY

**Diabetes is a leading cause
of blindness, kidney failure,
amputation, heart attack,
stroke, and premature death.**



DM COMPLICATIONS - SUMMARY

These complications can be minimized!

➤ **Glycemic Control Matters**

❖ **Early Diagnosis of DM**

❖ **Glycemic Control Matters**

❖ **Monitoring for complications**

❖ **Glycemic Control Matters**

❖ **Aggressive treatment of co-risk factors**

❖ **Glycemic Control Matters**

❖ **Team approach - access to multiple specialists**



DM COMPLICATIONS - SUMMARY

Glycemic Control Matters*

Thoughtfully applied in Type 2



DM COMPLICATIONS - SUMMARY

**Prevention
is more rewarding
than
Management
of Complications**